思路迪医药
3D Medicines

3D Medicines Inc.
思路迪医药股份有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1244)

UPDATE ON THE QUALIFICATION OF COMPANY SECRETARY; RESIGNATION OF JOINT COMPANY SECRETARY AND CHANGE OF AUTHORISED REPRESENTATIVE

Reference is made to the prospectus by 3D Medicines Inc. (the "**Company**") dated 29 November 2022 in relation to, among other things, the appointment of Ms. Xia Fang ("**Ms. Xia**") and Ms. Li Ching Yi ("**Ms. Li**") as the joint company secretaries of the Company (the "**Joint Company Secretaries**") and the waiver granted to the Company by The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") from strict compliance from Rules 3.28 and 8.17 of the Rules Governing the Listing of Securities on the Stock Exchange (the "**Listing Rules**") in relation to the qualification of Ms. Xia to act as one of the Joint Company Secretaries for a period from 15 December 2022 (the date of the Company's listing) to 14 December 2025.

The board of directors of the Company (the "**Board**") is pleased to announce that the Stock Exchange has confirmed that Ms. Xia, a current Joint Company Secretary, is qualified to act as the company secretary of the Company under Rules 3.28 and 8.17 of the Listing Rules. Accordingly, Ms. Li has tendered her resignation as a Joint Company Secretary and the authorised representative of the Company (the "**Authorised Representative**") under Rule 3.05 of the Listing Rules with effect from 30 June 2026.

Following Ms. Li's resignation, Ms. Xia will continue to serve as the sole company secretary of the Company.

The Board further announces that Ms. Xia has been appointed as the Authorised Representative with effect from 30 June 2026.

Ms. Li confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Stock Exchange and the shareholders of the Company.

The Board would like to express its gratitude to Ms. Li for her valuable contribution to the Company during her term of office.

By order of the Board
3D Medicines Inc.
Dr. Gong Zhaolong
Chairman of the Board

Hong Kong, 30 June 2026

As at the date of this announcement, the Board of Directors of the Company comprises Dr. GONG Zhaolong as executive Director, Mr. ZHU Jinqiao, Mr. ZHOU Feng and Ms. CHEN Yawen as non-executive Directors, and Dr. LI Jin, Dr. LIN Tat Pang and Mr. LIU Xinguang as independent non-executive Directors.